글로벌 연구동향
분자영상 및 방사화학
- 2019년 05월호
[J Control Release.] Theranostic iRGD peptide containing cisplatin prodrug: Dual-cargo tumor penetration for improved imaging and therapy.KIST / 조홍준, 김세훈*
- 출처
- J Control Release.
- 등재일
- 2019 Apr 28
- 저널이슈번호
- 300:73-80. doi: 10.1016/j.jconrel.2019.02.043. Epub 2019 Mar 1.
- 내용
Abstract
In theranostics, peptide-based platforms have widely been exploited owing to their unique biological functions and chemical versatilities. As a tumor-homing ligand, internalizing RGD peptide (iRGD), composed of a tumor-targeting sequence (RGD) and a cell-penetrating C-end Rule (CendR) motif, is known to facilitate the tumor-specific delivery of payloads that are covalently conjugated on its N-terminal fragment or co-administered without any covalent linkages. However, theranostic uses of the iRGD-based platform remain in its infancy with its full potential unexplored; for instance, detailed mechanism of iRGD fragmentation during internalization, strategies for the tumor-specific release of payloads from iRGD and the role of the C-terminal iRGD fragment in delivery have yet to be revealed. In this study, we designed a dual-channel fluorescent cyclic iRGD (TAMRA-iRGDC-Cy5.5) to track each of the N- and C-terminal fragments separately during the tumor internalization process. It turned out that both fragments undergo translocation into cancer cells together and are localized within endosomal-lysosomal compartments. The resulting co-internalization of both iRGD fragments allowed us to develop a new theranostic peptide platform (Cy5.5-iRGDC-Pt(IV)) by conjugating a fluorescent dye and a cisplatin prodrug on each terminus of cyclic iRGD for simultaneous cancer-targeted imaging and therapy. Compared to a control peptide having a non-iRGD sequence, the Cy5.5-iRGDC-Pt(IV) did not only provide a better tumor imaging contrast but also induced tumor-specific apoptosis leading to efficacious tumor suppression. Besides the outstanding cancer imaging and therapeutic performance, the Cy5.5-iRGDC-Pt(IV) revealed negligible systemic toxicity, holding potential to be applied for theranostic uses.
Author informationCho HJ1, Park SJ2, Lee YS3, Kim S4.
1
Center for Theragnosis, Korea Institute of Science and Technology, 5 Hwarang-ro 14-gil, Seongbuk-gu, Seoul 02792, Republic of Korea.
2
Center for Theragnosis, Korea Institute of Science and Technology, 5 Hwarang-ro 14-gil, Seongbuk-gu, Seoul 02792, Republic of Korea; School of Chemical and Biological Engineering, Seoul National University, Seoul 08826, Republic of Korea.
3
School of Chemical and Biological Engineering, Seoul National University, Seoul 08826, Republic of Korea.
4
Center for Theragnosis, Korea Institute of Science and Technology, 5 Hwarang-ro 14-gil, Seongbuk-gu, Seoul 02792, Republic of Korea; KU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul 02841, Republic of Korea; Division of Bio-Medical Science & Technology, KIST School, Korea University of Science and Technology (UST), Seoul 02792, Republic of Korea. Electronic address: sehoonkim@kist.re.kr.
- 키워드
- Cancer imaging and therapy; CendR pathway; Cisplatin prodrug; Internalizing iRGD; Theranostic peptide
- 덧글달기
- 이전글 [Clin Cancer Res.] A novel orally active inverse agonist of estrogen-related receptor gamma (ERRγ), DN200434, a booster of NIS in anaplastic thyroid cancer.
- 다음글 [Theranostics] Sonic hedgehog pathway activation is associated with cetuximab resistance and EPHB3 receptor induction in colorectal cancer
편집위원
이 논문에서 저자는 세포 투과를 가능하게 한 종양표적 RGD peptide (internalizing RGD, iRGD)에 이중 채널 광학영상이 가능하게끔 형광염료를 결합시킨 물질을 개발하였고, 이를 이용해 종양내 internalization 메커니즘 연구를 보여주었다. 이를 이용하여 종양의 진단 및 치료의 가능성을 제시하고 있다.
덧글달기닫기2019-05-28 18:00:19
등록